No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors

Petra J. Woestenberg*, Audrey J. King, Marianne A. B. van der Sande, Robine Donken, Suzan Leussink, Fiona R. M. van der Klis, Christian J. P. A. Hoebe, Johannes A. Bogaards, Birgit H. B. van Benthem, Med Microbiological Labs, Public Hlth Serv

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)393-400
Number of pages8
JournalJournal of Infection
Volume74
Issue number4
DOIs
Publication statusPublished - Apr 2017

Keywords

  • Human papillomavirus 6
  • Human papillomavirus 11
  • Condylomata acuminata
  • Warts
  • Vaccination
  • Human papillomavirus vaccine, L1 type 16, 18
  • Prevention & control
  • RISK HPV TYPES
  • GENITAL WARTS
  • INTRAEPITHELIAL NEOPLASIA
  • AS04-ADJUVANTED VACCINE
  • ANOGENITAL WARTS
  • CERVICAL-CANCER
  • PAPILLOMAVIRUS
  • NETHERLANDS
  • EFFICACY
  • WOMEN

Cite this

Woestenberg, P. J., King, A. J., van der Sande, M. A. B., Donken, R., Leussink, S., van der Klis, F. R. M., Hoebe, C. J. P. A., Bogaards, J. A., van Benthem, B. H. B., Med Microbiological Labs, & Public Hlth Serv (2017). No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors. Journal of Infection, 74(4), 393-400. https://doi.org/10.1016/j.jinf.2017.01.007